Syndax insider plans sale of 17,159 shares

Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32.

Accepted by SEC EDGAR 02/09/2026 - 03:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32. The shares were acquired on 02/06/2026 via restricted stock vesting as compensation. The planned sale is expected around 02/09/2026 on the NASDAQ. Over the prior three months, Metzger sold 7,412 common shares for gross proceeds of $152,836.18, also reported in the filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 filing for SNDX disclose?

The Form 144 shows insider Michael A. Metzger intends to sell 17,159 Syndax common shares, valued at $360,826.32, on NASDAQ through Fidelity. It also details prior three‑month sales and notes the shares came from restricted stock vesting as compensation.

How many Syndax (SNDX) shares is Michael A. Metzger planning to sell?

Michael A. Metzger plans to sell 17,159 common shares of Syndax. The filing lists an aggregate market value of $360,826.32 for this block, with the intended sale occurring around 02/09/2026 on NASDAQ via Fidelity Brokerage Services LLC.

How did Michael A. Metzger acquire the SNDX shares he plans to sell?

The 17,159 Syndax shares were acquired on 02/06/2026 through restricted stock vesting from the issuer as compensation. The filing identifies the nature of payment as “Compensation,” indicating they were not purchased for cash in the market.

What prior Syndax (SNDX) share sales has Michael A. Metzger reported?

Over the past three months, Metzger sold 7,412 Syndax common shares on 02/06/2026 for gross proceeds of $152,836.18. These historical transactions are listed alongside the new proposed sale in the disclosure schedule.

On which exchange and through which broker will the SNDX shares be sold?

The filing states the 17,159 Syndax common shares are expected to be sold on the NASDAQ. The designated broker is Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island, handling the planned Rule 144 transaction.

What is the approximate sale date in the SNDX Form 144 notice?

The notice lists an approximate sale date of 02/09/2026 for the 17,159 Syndax common shares. This date reflects when the insider expects to begin selling under Rule 144, subject to market conditions and applicable trading requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001507220
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Syndax Pharmaceuticals Inc
SEC File Number	001-37708
Address of Issuer	730 THIRD AVENUE 9TH FLOOR NEW YORK NEW YORK 10017
Phone	781-419-1400
Name of Person for Whose Account the Securities are To Be Sold	Metzger Michael A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	17159	360826.32	86914838	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/06/2026	Restricted Stock Vesting	Issuer			17159	02/06/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael A. Metzger 35 Gatehouse Drive Building D, Floor 3 Waltham MA 02451	Common	02/06/2026	7412	152836.18

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Michael A. Metzger
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)